Beyond Air Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Beyond Air in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Beyond Air stock.
View analyst ratings for Beyond Air or view top-rated stocks.

Wall Street analysts have given Beyond Air a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Beyond Air wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Beyond Air is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Beyond Air.

Beyond Air, Inc. (NASDAQ:XAIR) posted its quarterly earnings results on Wednesday, June, 9th. The company reported ($0.24) EPS for the quarter, beating analysts' consensus estimates of ($0.31) by $0.07. Beyond Air had a negative trailing twelve-month return on equity of 133.04% and a negative net margin of 2,617.28%.
View Beyond Air's earnings history.

Beyond Air's stock was trading at $5.32 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, XAIR stock has increased by 3.6% and is now trading at $5.51.
View which stocks have been most impacted by COVID-19.

3 equities research analysts have issued 12-month price objectives for Beyond Air's shares. Their forecasts range from $9.00 to $12.00. On average, they anticipate Beyond Air's stock price to reach $11.00 in the next year. This suggests a possible upside of 99.6% from the stock's current price.
View analysts' price targets for Beyond Air or view top-rated stocks among Wall Street analysts.

Some companies that are related to Beyond Air include ClearPoint Neuro (CLPT), Neuronetics (STIM), InfuSystem (INFU), Accuray (ARAY), Retractable Technologies (RVP), Profound Medical (PROF), Cytosorbents (CTSO), IRadimed (IRMD), Apyx Medical (APYX), The Westaim (WEDXF), DarioHealth (DRIO), Utah Medical Products (UTMD), Nemaura Medical (NMRD), Co-Diagnostics (CODX) and Apollo Endosurgery (APEN).
View all of XAIR's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Beyond Air investors own include OPKO Health (OPK), NVIDIA (NVDA), Pfizer (PFE), Axsome Therapeutics (AXSM), BioCryst Pharmaceuticals (BCRX), Enphase Energy (ENPH), General Motors (GM), Livongo Health (LVGO), Main Street Capital (MAIN) and Ollie's Bargain Outlet (OLLI).

Beyond Air trades on the NASDAQ under the ticker symbol "XAIR."

Beyond Air's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.67%), Geode Capital Management LLC (1.19%), Northern Trust Corp (1.02%), Flagship Harbor Advisors LLC (0.58%), Ameriprise Financial Inc. (0.50%) and Squarepoint Ops LLC (0.23%). Company insiders that own Beyond Air stock include Amir Avniel, Douglas Beck, Robert Carey, Ron Bentsur and Steven A Lisi.
View institutional ownership trends for Beyond Air.

XAIR stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Ameriprise Financial Inc., Northern Trust Corp, and Baldwin Brothers Inc. MA. Company insiders that have sold Beyond Air company stock in the last year include Amir Avniel, and Ron Bentsur.
View insider buying and selling activity for Beyond Air or view top insider-selling stocks.

XAIR stock was bought by a variety of institutional investors in the last quarter, including Flagship Harbor Advisors LLC, BlackRock Inc., Geode Capital Management LLC, Virtu Financial LLC, GSA Capital Partners LLP, Goldman Sachs Group Inc., Squarepoint Ops LLC, and Millennium Management LLC. Company insiders that have bought Beyond Air stock in the last two years include Amir Avniel, Douglas Beck, Robert Carey, and Steven A Lisi.
View insider buying and selling activity for Beyond Air or or view top insider-buying stocks.

Shares of XAIR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of XAIR stock can currently be purchased for approximately $5.51.

Beyond Air has a market capitalization of $112.90 million and generates $870,000.00 in revenue each year. The company earns $-19,940,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis.

Beyond Air employs 23 workers across the globe.

The official website for Beyond Air is www.ait-pharm.com.

Beyond Air is headquartered at 825 EAST GATE BOULEVARD SUITE 320, GARDEN CITY NY, 11530.

Beyond Air's mailing address is 825 EAST GATE BOULEVARD SUITE 320, GARDEN CITY NY, 11530. The company can be reached via phone at 516-665-8200.